Atika Capital Management LLC Makes New $3.33 Million Investment in Maze Therapeutics, Inc. $MAZE

Atika Capital Management LLC purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,500 shares of the company’s stock, valued at approximately $3,328,000.

Other large investors also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics during the fourth quarter worth about $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics during the fourth quarter worth about $43,000. California State Teachers Retirement System lifted its holdings in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after acquiring an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. This trade represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the completion of the transaction, the chief marketing officer owned 15,000 shares in the company, valued at $393,300. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 141,470 shares of company stock worth $3,887,939. 5.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Truist Financial reduced their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Trading Down 2.8%

Shares of Maze Therapeutics stock opened at $27.69 on Friday. The business has a fifty day simple moving average of $27.06 and a 200-day simple moving average of $34.51. Maze Therapeutics, Inc. has a fifty-two week low of $12.81 and a fifty-two week high of $53.65. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -10.94 and a beta of 2.14. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. On average, equities analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.